2021 Preliminary Program

PRELIMINARY PROGRAM 

Working titles/topics shown. Final titles and speakers will follow 

The health and safety of San Antonio Breast Cancer Symposium attendees, exhibitors, and staff is a top 
priority. Please click here for further information.


EDUCATIONAL SESSIONS

Most of the presentations at SABCS focus on the latest clinical and basic research results relating to breast cancer. By contrast, educational sessions are designed to inform and update those interested in a review on a particular topic. Although these sessions may include new specific research findings, their primary intent is to offer summaries of existing knowledge, and to provide background for some of the active areas which will be discussed in the rest of the meeting.

Artificial Intelligence: Beyond the Soundbites
Jorge S. Reis-Filho, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Everything you always wanted to know about AI but were afraid to ask 
Regina Barzilay, PhD
MIT
Cambridge, MA

Artificial intelligence: Guiding the pathologists' eyes
TBA

Artificial intelligence in radiology
TBA 

Refining Heredity Risk
Moderator: Olufunmilayo (Funmi) Olopade, MD, FACP
University of Chicago
Chicago, IL

Reclassifying VUS: New techniques can solve the puzzle once and for all
TBA

Clinical management of moderate penetrance genes
Allison W. Kurian, MBBS, MD, MSc
Stanford University School of Medicine
Palo Alto, CA

Polygenic risk score: Should clinicians use it
Montse Garcia-Closas, MD, DrPH
National Cancer Institute
Rockville, MD

Panel Discussion

Triple Positive Breast Cancer
Moderator: Jenny C. Chang, MD, MB BChir
Houston Methodist Hospital
Houston, TX

The ideal partner to HER2 directed therapies
Sara A. Hurvitz, MD
UCLA
Los Angeles, CA

ER/HER2+ cross talk
Charles M. Perou, PhD
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Escalating and de-escalation - titrating the right regimen in early stage HER2 positive 
Nadia Harbeck, MD, PhD
University of Munich
Munich, Germany

Triple Negative Breast Cancer: Critical Update on Biology and Management
Moderator: Rita Nanda, MD
University of Chicago
Chicago, IL

Genomic and transcriptomic landscape of TNBC
Zhi-Ming Shao, MD
Fudan University of Shanghai
Shanghai, China

Optimizing the management of early stage TNBC
Elizabeth A. Mittendorf, MD, PhD
Dana-Farber Brigham and Women's Cancer Center
Boston, MA

Management of special subtypes of TNBC
Alexandra Thomas, MD, FACP
Wake Forest Baptist Health
Winston-Salem, NC

Emerging Adjuvant Therapies: What's Ready for Prime Time?
Moderator: Angela DeMichele, MSCE
University of Pennsylvania
Philadelphia, PA

Approving new therapies
TBA

CDK4/6 for ER+
Ingrid A. Mayer, MD, MSCI
Vanderbilt-Ingram Cancer Center
Nashville, TN


IO vs Capecitabine for TNBC
Sherene Loi, MD, PhD
Peter MacCallum Cancer Centre
Melbourne, Australia

PARP for BRCA+ breast cancers
Andrew Tutt, MD
Institute of Cancer Research
London, United Kingdom

Evidence Based Integrative Therapies - During and Beyond Treatment
Moderator: Dawn L. Hershman, MD, MS
Columbia University Herbert Irving Comprehensive Cancer Center
New York, NY

Acupuncture
Ting Bao, MD, DABMA, MS
Memorial Sloan Kettering Cancer Center
New York, NY

Hypnosis and mindfulness
David Spiegel, MD
Stanford University
Stanford, CA


Complementary treatments
TBA

What does diet and exercise change really do for you
Nicole Simone, MD
Thomas Jefferson University
Philadelphia, PA

Panel Discussion

Fine Tuning Risk Assessment and Risk Reduction 
Moderator: Banu Arun, MD
UT MD Anderson Cancer Center
Houston, TX

Lifestyle: Exercise and diet
Neil M. Iyengar, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Emergent pharmacologic interventions for prevention: Non endocrine treatments
Brandy Heckman, PhD, MPH
National Cancer Institute
Rockville, MD

Imaging/AI
Constance Lehman, MD, PhD
Massachusetts General Hospital
Boston, M

Panel Discussion
Ashley A. Dedmon

Local Therapy of the Primary and Beyond in Patients with Advanced Disease 
Moderator: Rajendra A. Badwe, MBBS, MS
Tata Memorial Centre
Mumbai, India

Local therapy of the primary tumor
Seema Khan, MD
Northwestern University
Chicago, IL

Special indications where local therapy should be considered
Anthony Lucci, MD
UT MD Anderson Cancer Center
Houston, TX

Oligo-progressive disease. Treating locally more than systemically
Amy Xu, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Anti-cancer Immune Response
Moderator: Justin Balko, PharmD, PhD
Vanderbilt University Medical Center
Nashville, TN

Understanding the anti-cancer immune response: Innate and adaptive responses to cancer cells
Laurence Zitvogel, MD, PhD
Institut Gustave Roussy
Villejuif, France

Micro and macro: Macrophage and microbiome diversity in the breast cancer microenvironment
Jennifer L. Guerriero, PhD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Optimizing immunotherapy efficacy in the clinic through biomarkers: Advances in single cell and spatial histology analyse
Marleen Kok, MD, PhD
The Netherlands Cancer Institute
Amsterdam, Netherland

Clinical Updates on Immunotherapy
Moderator: Peter Schmid, MD, PhD
Bart's Cancer Institute Queen Mary University of London
London, United Kingdom

Immunotherapy in the metastatic setting - chemo backbone and biomarker
Rebecca Dent, MD
National Cancer Center
Singapore

Immune therapy in the (neo) adjuvant setting
Heather L. McArthur, MD, MPH
Cedars-Sinai Medical Center
Los Angeles, CA

IO beyond TNBC
Giuseppe Curigliano, MD, PhD
European Institute of Oncology
Milan, Italy

The Fluid Landscape of Liquid Biopsy
Nicholas Turner, PhD, FRCF
The Royal Marsden Hospital Institute of Cancer Research
London, United Kingdom

Monitoring of advanced breast cancer with liquid biopsies
Francois Clement-Bidard, MD, PhD
Institut Curie
Paris, France

Single cell analysis of circulating tumor cells
Shyamala  Maheswaran, PhD
Massachusetts General Hospital
Boston, MA

Challenges in early detection - screening and MRD
Pedram Razavi MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Targeting the "Un-druggable"
Moderator: Funda Meric-Bernstam, MD
UT MD Anderson Cancer Center
Houston, TX

Targeting EZH2 functions
Celina G. Kleer, MD
University of Michigan Medical School
Ann Arbor, MI

RNA metabolism and splicing
Trey Westbrook, PhD
Baylor College of Medicine
Houston, TX

Novel epigenomic targets in TNBC
David W. Cescon, MD, PhD
Princess Margaret Cancer Centre
Toronto, Canada

SABCS with the Society of Surgical Oncology present Local Therapy - Management of the Axilla
Moderator: Hiram (Chip) Cody, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Axillary management in upfront surgery - staging, local control or both?
Stephanie Wong, MD, MPH
McGill University
Montreal, Canada

Refining axillary management after neoadjuvant chemotherapy - what does the evidence support
Eleftherios (Terry) Mamounas, MD, MPH, FACS
Orlando Health Cancer Institute
Orlando, FL

Can radiation replace ALND after + SLNB
Reshma Jagsi, MD, DPhil
University of Michigan
Ann Arbor, MI

Options for reducing risk for lymphedema when ALND/regional nodal XRT are needed
Hani Sbitany, MD
Mount Sinai
New York, NY

Top

 



 

William L. McGuire Memorial Lecture

AACR Distinguished Lectureship in Breast Cancer Research

AACR Outstanding Investigator Award for Breast Cancer Research

Susan G. Komen® Brinker Awards

Top



Genomic Profiling in Early Stage ER Positive Breast Cancers/Precision Medicine
Mitchell Dowsett, PhD
Royal Marsden Hospital
London, United Kingdom

Triple Negative Breast Cancer Heterogeneity - Addressing the Pitfalls of Past Research and Future Therapeutic Targets
Lisa A. Carey, MD, ScM, FASCO
University of North Carolina at Chapel Hill
Chapel Hill, NC

Top



DNA Repair in Breast Cancer: Diagnosis and Treatment
Moderator: TBA

CRISPR screens to identify novel DNA repair defects synthetic lethal therapies
Daniel Durocher
Lunenfeld-Tanenbaum Research Institute
Toronto, Canada

Genomics of DNA repair defects in breast cancer
Serena Nik-Zainal, PhD
University of Cambridge
Cambridge, United Kingdom

Targeting DNA damage response and HRD in breast cancer
Timothy A. Yap, MBBS, PhD, FRCP
UT MD Anderson Cancer Center
Houston, TX

The Evolution of Local Therapy in the Genomic Era
Moderator: Tari King, MD
Brigham and Women's Hospital
Boston, MA

Is less (or more) axillary surgery needed in the genomic era?
Monica Morrow, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Can genomic risk be used to tailor radiation therapy?
Philip Poortmans, PhD
Iridium Netwerk
Paris, France

Top





 



Moderator: Carlos L. Arteaga, MD
Harold C. Simmons Comprehensive Cancer Center
UT Southwestern
Dallas, TX

Basic science
Xiang Zhang, PhD
Baylor School of Medicine
Houston, TX

Translational research
Christina Curtis
Stanford Medicine
Stanford, CA

Early breast cancer   
Foluso Ademuyiwa, MD
Washington University School of Medicine
Saint Louis, MO

Advanced breast cancer
Peter Schmid, MD, PhD
Bart's Cancer Institute Queen Mary University of London
London, United Kingdom

Top
 



Targeting Nuclear Steroid Receptors
Moderator: Carol Lange, PhD
University of Minnesota
Minneapolis, MN

AR
Wayne Tilley
The University of Adelaide
Adelaide, Australia

PR
Christy R. Hagan, PhD
University of Kansas Medical Center
Kansas City, KS

GR
Suzanne Conzen, MD
UT Southwestern Medical Center
Dallas, TX

Top



HER2 Heterogeneity
Matthew J. Ellis, MB, BChir, BSc., PhD, FRCP
Baylor College of Medicine
Houston, TX

Basic
TBA

Heterogeneity in treatment outcomes for HER2+ breast cancer – Clinical management strategies
Sara M. Tolaney, MD, MPH
Dana Farber Cancer Institute
Boston, MA

Molecular heterogeneity in HER2+ breast cancer – can outcomes be predicted?
Aleix Prat, MD, PhD
Hospital Clinic Barcelona
Barcelona, Spain

ER Mutations and SERDS
Moderator: Fabrice Andre, MD, PhD
Institut Gustave Roussy
Villejuif, France

Next generation sequencing in ER targets
Donald P. McDonnell, PhD
Duke University School of Medicine
Durham, NC 

ER+ word salad decoded: SERD, SERM, SERCA, CERAN, PROTAC
Komal Jhaveri, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Top



The Promise and Reality of Oligometastatic Ablation for Breast Cancer
Moderator: Steven J. Chmura, MD, PhD
University of Chicago
Chicago, IL

Oligometastatic disease: Definitions and practice patterns
Yolande Lievens, MD, PhD
UZ Gent
Ghent, Belgium

OMD data and gaps in breast cancer
David Palma, MD, PhD
London Health Sciences Center
Ontario, Canada

Top



Clinical Research: From Study Design to Scientific Presentation
Moderator: Aditya Bardia, MD, MPH
Massachusetts General Hospital
Boston, MA

How to select biomarkers rationally
Justin Balko, PharmD, PhD
Vanderbilt University Medical Center
Nashville, TN

How to design an efficient clinical study
Valentina Nekljudova, PhD
German Breast Group
Neu Isenburg, German

How to include patient advocates in clinical research
Patty Spears
University of North Carolina at Chapel Hill
Chapel Hill, NC

How to present clinical research results effectively
George W. Sledge, Jr, MD
Stanford University School of Medicine
Stanford, C


Basic Workshop: Basic Science for Breast Oncologists
Moderator: Alan Welm, PhD
University of Utah Huntsman Cancer Institute
Salt Lake City, UT

Genome editing in human organoids as new models for discovery
TBA

In silico experimentation from your living room: Tools to access and analyze existing datasets
Daniel Stover, MD
Ohio State University Comprehensive Cancer Center
Columbus, OH

Tricking T cells into action: Using patient-derived organoids to identify and expand tumor-specific T cells
Senthil K. Muthuswamy, Phd
Beth Israel Deaconess Medical Center
Boston, MA

Meeting the bar: How to tell when basic science discoveries are ready to translate
Bora Lim, MD
UT MD Anderson Cancer Center
Houston, TX



Top



                                                                                                                       

Clinical
Moderator: Matthew P. Goetz, MD
Mayo Clinic
Rochester, MN

Panelists:
Thelma Brown
Boon Chua
Hope Rugo
Anne Vincent-Solomon
Lee Wilke       

Molecular Tumor Board
Moderator: Ben Ho Park, MD, PhD
Vanderbilt University Medical Center
Nashville, TN

Panelists:
Fabrice Andre
Mark Burkhard
Sarat Chandarlapaty
Susan Domchek
Diana Mandelker
Milan Radovich
Bob Riter                                                                                                                   



CAREER DEVELOPMENT FORUMNETWORKING SESSION FOR YOUNG INVESTIGATORS

                                                                                                               

The session is open to early-career scientists, defined as graduate students, postdoctoral or clinical fellows, or medical students and residents, who are registered attendees of the 2021 SABCS. Space in the workshop is limited. Preregistration is not required.

Limited to 120-150 participants; registrations will be accepted on a first-come, first-served basis and are free of charge. Badges are required and will be scanned at the door for registration. Attendees should be prepared to visit 3-4 tables during the session. Attendees will be asked to rotate tables every 20 minutes                                                                                                                             

Top



Regulatory

Trust in Science

COVID Update

Translating Biomarkers Into the Clinic

Building a Successful Academic Breast Cancer Program

  


One Week of Whole Breast RT is the New Standard of Care
Chair: Wendy A. Woodward, MD, PhD
UT MD Anderson Cancer Center
Houston, TX

Pro
Charlotte E. Coles, PhD
University of Cambridge
Cambridge, United Kingdom

Con
Julia White, MD
The Ohio State University
Columbus, OH

RxPONDER: Was it all OFS?
Chair: Harold Burstein MD, PhD
Dana-Farber Cancer Institute
Boston, MA

Pro
Michael Gnant, MD
Medical University of Vienna
Vienna, Austria

Con
Sibylle Loibl, Dr Med
GBG Forschungs GMBH
Hessen, Germany





 


        Moderator: Stephen Johnston, MD, PhD
        The Royal Marsden Hospital
London, United Kingdom

        Panel Members

        Carlos Barrios
Tom Bruan
Javier Cortes
Erica Hamilton
Meena Moran
Ann Partridge
Jorge Reis-Filho
Ivis Sampayo
Alistair Thompson


 PRELIMINARY SCHEDULE

Hours subject to change


Monday, December 6 Registration  12:00 PM - 5:00 PM 
Tuesday, December 7  Registration  8:00 AM - 5:00 PM
  Program  8:00 AM - 7:00 PM 
Wednesday, December 8 Registration  7:00 AM - 5:00 PM 
  Program 8:00 AM - 7:00 PM 
  Exhibits  10:00 AM - 5:00 PM 
Thursday, December 9  Registration  6:45 AM - 4:00 PM 
  Program  8:00 AM - 7:00 PM 
  Exhibits  10:00 AM - 5:00 PM 
Friday, December 10  Registration  6:45 AM - 3:00 PM 
  Program  8:00 AM - 7:00 PM 
  Exhibits  10:00 AM - 5:00 PM 

Top

Clinical Research Workshop

Mod